Nicotine receptor partial agonists for smoking cessation
- PMID: 21154363
- DOI: 10.1002/14651858.CD006103.pub4
Nicotine receptor partial agonists for smoking cessation
Update in
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103. doi: 10.1002/14651858.CD006103.pub6. PMID: 21328282 Updated. Review.
Abstract
Background: Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine receptor partial agonist from cytisine, a drug widely used in central and eastern Europe for smoking cessation. The first trial reports of varenicline were released in 2006, and further trials have now been published or are currently underway.
Objectives: The primary objective of this review is to assess the efficacy and tolerability of nicotine receptor partial agonists, including varenicline and cytisine, for smoking cessation.
Search strategy: We searched the Cochrane Tobacco Addiction Group's specialised register for trials, using the terms ('varenicline' or 'cytisine' or 'Tabex' or 'nicotine receptor partial agonist') and 'smoking' in the title or abstract, or as keywords. We also searched MEDLINE, EMBASE, PsycINFO and CINAHL using MeSH terms and free text, and we contacted authors of trial reports for additional information where necessary. The latest search was in September 2010.
Selection criteria: We included randomized controlled trials which compared the treatment drug with placebo. We also included comparisons with bupropion and nicotine patches where available. We excluded trials which did not report a minimum follow-up period of six months from start of treatment.
Data collection and analysis: We extracted data on the type of participants, the dose and duration of treatment, the outcome measures, the randomization procedure, concealment of allocation, and completeness of follow up.The main outcome measured was abstinence from smoking after at least six months from the beginning of treatment. We used the most rigorous definition of abstinence, and preferred biochemically validated rates where they were reported. Where appropriate we performed meta-analysis to produce a risk ratio, using the Mantel-Haenszel fixed-effect model.
Main results: We found 11 trials of varenicline compared with placebo for smoking cessation; three of these included a bupropion experimental arm. We also found one relapse prevention trial, comparing varenicline with placebo, and two open-label trials comparing varenicline with nicotine replacement therapy (NRT). We also include one trial in which all the participants were given varenicline, but received behavioural support either online or by phone calls, or by both methods. This trial is not included in the analyses, but contributes to the data on safety and tolerability. The included studies covered >10,300 participants, 6892 of whom used varenicline. We identified one trial of cytisine (Tabex) for inclusion.The pooled risk ratio (RR) (10 trials, 4443 people, excluding one trial evaluating long term safety) for continuous abstinence at six months or longer for varenicline at standard dosage versus placebo was 2.31 (95% confidence interval [CI] 2.01 to 2.66). Varenicline at lower or variable doses was also shown to be effective, with an RR of 2.09 (95% CI 1.56 to 2.78; 4 trials, 1272 people). The pooled RR for varenicline versus bupropion at one year was 1.52 (95% CI 1.22 to 1.88; 3 trials, 1622 people). The RR for varenicline versus NRT for point prevalence abstinence at 24 weeks was 1.13 (95% CI 0.94 to 1.35; 2 trials, 778 people). The two trials which tested the use of varenicline beyond the 12-week standard regimen found the drug to be well-tolerated during long-term use. The main adverse effect of varenicline was nausea, which was mostly at mild to moderate levels and usually subsided over time. Post-marketing safety data raised questions about a possible association between varenicline and depressed mood, agitation, and suicidal behaviour or ideation. The labelling of varenicline was amended in 2008, and the manufacturers produced a Medication Guide. Thus far, surveillance reports and secondary analyses of trial data lend little support to a causal relationship.The one cytisine trial included in this review found that more participants taking cytisine stopped smoking compared with placebo at two-year follow up, with an RR of 1.61 (95% CI 1.24 to 2.08).
Authors' conclusions: Varenicline at standard dose increased the chances of successful long-term smoking cessation between two- and threefold compared with pharmacologically unassisted quit attempts. Lower dose regimens also conferred benefits for cessation, while reducing the incidence of adverse events. More participants quit successfully with varenicline than with bupropion. Two open-label trials of varenicline versus NRT suggested a modest benefit of varenicline but confidence intervals did not rule out equivalence. Limited evidence suggests that varenicline may have a role to play in relapse prevention. The main adverse effect of varenicline is nausea, but mostly at mild to moderate levels and tending to subside over time. Possible links with serious adverse events, including depressed mood, agitation and suicidal thoughts, have been reported but are so far not substantiated.There is a need for further independent community-based trials of varenicline, to test its efficacy and safety in smokers with varying co-morbidities and risk patterns. There is a need for further trials of the efficacy of treatment extended beyond 12 weeks. Cytisine may also increase the chances of quitting, but the evidence at present is inconclusive.
Update of
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2010 Dec 08;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. PMID: 18646137 Updated. Review.
Comment in
-
Varenicline increases smoking abstinence at 6 months to a year compared with placebo or bupropion; nausea is the most commonly reported adverse effect.Evid Based Med. 2011 Aug;16(4):113-4. doi: 10.1136/ebm1200. Epub 2011 Mar 9. Evid Based Med. 2011. PMID: 21393304 Free PMC article. No abstract available.
Similar articles
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103. doi: 10.1002/14651858.CD006103.pub6. PMID: 21328282 Updated. Review.
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103. doi: 10.1002/14651858.CD006103.pub6. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2016 May 09;(5):CD006103. doi: 10.1002/14651858.CD006103.pub7. PMID: 22513936 Updated. Review.
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2010 Dec 08;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. PMID: 18646137 Updated. Review.
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2016 May 9;2016(5):CD006103. doi: 10.1002/14651858.CD006103.pub7. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2023 May 5;5:CD006103. doi: 10.1002/14651858.CD006103.pub8. PMID: 27158893 Free PMC article. Updated. Review.
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006103. doi: 10.1002/14651858.CD006103.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. PMID: 17253581 Updated. Review.
Cited by
-
Nicotine receptor partial agonists for smoking cessation.Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8. Cochrane Database Syst Rev. 2023. PMID: 37142273 Free PMC article. Review.
-
Exploring the interoceptive stimulus effects of nicotine and varenicline.Pharmacol Biochem Behav. 2019 Jun;181:9-16. doi: 10.1016/j.pbb.2019.04.001. Epub 2019 Apr 4. Pharmacol Biochem Behav. 2019. PMID: 30954637 Free PMC article.
-
[Psychotherapy and pharmacotherapy for harmful tobacco use and tobacco dependency].Nervenarzt. 2016 Jan;87(1):35-45. doi: 10.1007/s00115-015-0037-1. Nervenarzt. 2016. PMID: 26666768 German.
-
European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).Int J Behav Med. 2012 Dec;19(4):403-88. doi: 10.1007/s12529-012-9242-5. Int J Behav Med. 2012. PMID: 23093473 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical